Novo A/s 13F annual report
Novo A/s is an investment fund managing more than $1.85 trillion ran by Barbara Due. There are currently 38 companies in Mrs. Due’s portfolio. The largest investments include Vanguard Index Fds and Brookfield Corp, together worth $439 billion.
$1.85 trillion Assets Under Management (AUM)
As of 13th August 2024, Novo A/s’s top holding is 1,038,550 shares of Vanguard Index Fds currently worth over $278 billion and making up 15.0% of the portfolio value.
In addition, the fund holds 3,880,230 shares of Brookfield Corp worth $161 billion.
The third-largest holding is Tempus Ai Inc worth $143 billion and the next is Asml Holding N V worth $136 billion, with 133,336 shares owned.
Currently, Novo A/s's portfolio is worth at least $1.85 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Novo A/s
The Novo A/s office and employees reside in Hellerup, Denmark. According to the last 13-F report filed with the SEC, Barbara Due serves as the General Counsel at Novo A/s.
Recent trades
In the most recent 13F filing, Novo A/s revealed that it had opened a new position in
Vanguard Index Fds and bought 1,038,550 shares worth $278 billion.
The investment fund also strengthened its position in Vaxcyte by buying
105,000 additional shares.
This makes their stake in Vaxcyte total 950,000 shares worth $71.7 billion.
Vaxcyte dropped approximately 0.1% in the past year.
On the other hand, there are companies that Novo A/s is getting rid of from its portfolio.
Novo A/s closed its position in Edgewise Therapeutics Inc on 20th August 2024.
It sold the previously owned 6,344,430 shares for $116 billion.
Barbara Due also disclosed a decreased stake in Asml Holding N V by 0.3%.
This leaves the value of the investment at $136 billion and 133,336 shares.
One of the largest hedge funds
The two most similar investment funds to Novo A/s are Cinctive Capital Management L.P. and Moors & Cabot. They manage $1.86 trillion and $1.85 trillion respectively.
Barbara Due investment strategy
Novo A/s’s portfolio is diversified across 5 sectors.
Currently, their heaviest sector is Health Care — making up 25.2% of
the total portfolio value.
The fund focuses on investments in the United States as
39.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
11% of the total holdings value.
On the other hand, small-cap stocks make up only 5.3% of the portfolio.
The average market cap of the portfolio companies is close to $128 billion.
The complete list of Novo A/s trades based on 13F SEC filings
These positions were updated on August 20th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Vanguard Index Fds |
Opened
1,038,550
|
$277,822,510,000 | 14.98% |
| Brookfield Corp |
No change
3,880,230
|
$161,184,754,000 | 8.69% |
| Tempus Ai Inc |
Opened
4,074,419
|
$142,604,665,000 | 7.69% |
| Asml Holding N V |
26.95%
133,336
|
$136,366,727,000 | 7.35% |
| Salesforce Inc |
No change
480,160
|
$123,449,136,000 | 6.66% |
| Edgewise Therapeutics Inc |
Closed
6,344,430
|
$115,722,403,000 | |
| Edgewise Therapeutics Inc |
Opened
6,344,430
|
$114,263,184,000 | 6.16% |
| Corcept Therapeutics Inc |
No change
2,411,362
|
$78,345,151,000 | 4.22% |
| Vaxcyte, Inc. |
12.43%
950,000
|
$71,734,500,000 | 3.87% |
| Insmed Inc |
40.27%
800,000
|
$53,600,000,000 | 2.89% |
| Mirum Pharmaceuticals Inc |
No change
1,500,000
|
$51,285,000,000 | 2.76% |
| Crinetics Pharmaceuticals In |
8.98%
1,000,000
|
$44,790,000,000 | 2.41% |
| Cable One Inc |
No change
118,403
|
$41,914,662,000 | 2.26% |
| Biomarin Pharmaceutical Inc. |
8.89%
490,000
|
$40,341,700,000 | 2.17% |
| Merus N.V |
Opened
675,000
|
$39,939,750,000 | 2.15% |
| Apple Inc |
No change
182,960
|
$38,535,035,000 | 2.08% |
| Alibaba Group Hldg Ltd |
No change
500,827
|
$36,059,544,000 | 1.94% |
| Pharvaris N V |
47.68%
1,725,000
|
$32,430,000,000 | 1.75% |
| Celldex Therapeutics Inc. |
Opened
850,000
|
$31,458,500,000 | 1.70% |
| 4d Molecular Therapeutics In |
No change
1,400,000
|
$29,386,000,000 | 1.58% |
| Lanzatech Global Inc |
No change
15,814,845
|
$29,257,463,000 | 1.58% |
| Alnylam Pharmaceuticals Inc |
No change
118,383
|
$28,767,069,000 | 1.55% |
| Arrivent Biopharma Inc |
39.26%
1,500,000
|
$27,825,000,000 | 1.50% |
| Viridian Therapeutics Inc |
81.82%
2,000,000
|
$26,020,000,000 | 1.40% |
| Cargo Therapeutics Inc |
23.52%
1,544,000
|
$25,352,480,000 | 1.37% |
| Amicus Therapeutics Inc |
No change
2,500,000
|
$24,800,000,000 | 1.34% |
| Brookfield Asset Managmt Ltd |
No change
627,207
|
$23,865,226,000 | 1.29% |
| Rocket Pharmaceuticals Inc |
4.76%
1,100,000
|
$23,683,000,000 | 1.28% |
| Lexeo Therapeutics Inc |
11.46%
1,450,500
|
$23,266,020,000 | 1.25% |
| Blueprint Medicines Corp |
51.20%
175,000
|
$18,861,500,000 | 1.02% |
| Inspire Med Sys Inc |
Closed
65,524
|
$14,073,900,000 | |
| Kyverna Therapeutics Inc |
150.00%
1,750,000
|
$13,125,000,000 | 0.71% |
| Morphic Hldg Inc |
Opened
375,000
|
$12,776,250,000 | 0.69% |
| Verve Therapeutics Inc |
20.00%
2,400,000
|
$11,712,000,000 | 0.63% |
| Metagenomi Inc |
3.50%
1,800,000
|
$7,344,000,000 | 0.40% |
| Io Biotech Inc |
12.95%
4,429,449
|
$5,182,455,000 | 0.28% |
| Treace Med Concepts Inc |
Closed
360,000
|
$4,698,000,000 | |
| AbCellera Biologics Inc. |
No change
1,126,915
|
$3,335,668,000 | 0.18% |
| Marqeta Inc |
No change
441,558
|
$2,419,738,000 | 0.13% |
| Galecto Inc. |
No change
2,497,791
|
$1,183,953,000 | 0.06% |
| Spero Therapeutics Inc |
No change
468,902
|
$609,573,000 | 0.03% |
| No transactions found | |||
| Showing first 500 out of 41 holdings | |||
Hedge funds similar to Novo A/s
- Weitz Investment Management, Inc
- Distillate Capital Partners
- Patient Capital Management
- Invenomic Capital Management L.P.
- Polaris Capital Management
- Foundry Partners
- Cinctive Capital Management L.P.
- Moors & Cabot
- Calamos Wealth Management
- Trust Co Of Vermont
- Capital Asset Advisory Services
- Gentrust
- Theleme Partners LL.P.
- Woodley Farra Manion Portfolio Management Inc